Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of “Moderate Buy” by Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $32.50.

GLUE has been the subject of several analyst reports. Guggenheim reduced their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Wells Fargo & Company reduced their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. upped their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Zacks Research lowered Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Finally, Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $18.15 on Friday. The business’s fifty day moving average price is $17.80 and its 200-day moving average price is $17.73. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -12.26 and a beta of 1.62. Monte Rosa Therapeutics has a 1-year low of $3.81 and a 1-year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Equities research analysts anticipate that Monte Rosa Therapeutics will post -1.23 EPS for the current year.

Insider Transactions at Monte Rosa Therapeutics

In other news, insider Philip Nickson sold 5,845 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the sale, the insider directly owned 55,000 shares in the company, valued at $972,950. This represents a 9.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $17.92, for a total value of $97,950.72. Following the completion of the sale, the chief executive officer owned 613,471 shares of the company’s stock, valued at $10,993,400.32. This trade represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 37,150 shares of company stock worth $668,694 in the last three months. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GLUE. State Street Corp raised its holdings in Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after acquiring an additional 1,260,707 shares during the period. MPM Bioimpact LLC bought a new stake in Monte Rosa Therapeutics during the fourth quarter valued at about $18,399,000. AQR Capital Management LLC raised its holdings in Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after acquiring an additional 1,054,406 shares during the period. Braidwell LP bought a new stake in Monte Rosa Therapeutics during the fourth quarter valued at about $14,870,000. Finally, Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics during the third quarter valued at about $5,928,000. 79.96% of the stock is owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.